<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00543192</url>
  </required_header>
  <id_info>
    <org_study_id>CC07703</org_study_id>
    <secondary_id>H-2007-0204</secondary_id>
    <secondary_id>A532820</secondary_id>
    <secondary_id>SMPH/OBSTET &amp; GYNECOL</secondary_id>
    <nct_id>NCT00543192</nct_id>
  </id_info>
  <brief_title>Sexual Functioning in Endometrial Cancer</brief_title>
  <official_title>Sexual Functioning in Endometrial Cancer Survivors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Wisconsin, Madison</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Wisconsin, Madison</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is estimate how sexual function in endometrial cancer survivors
      varies with severity of disease.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2007</start_date>
  <completion_date type="Actual">June 2009</completion_date>
  <primary_completion_date type="Actual">June 2009</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Female Sexual Function Index (FSFI).</measure>
    <time_frame>at time of enrollment</time_frame>
  </primary_outcome>
  <enrollment type="Actual">73</enrollment>
  <condition>Endometrial Cancer</condition>
  <condition>Sexual Function</condition>
  <eligibility>
    <study_pop>
      <textblock>
        University of Wisconsin Gynecologic Oncology and Radiation Oncology Clinics
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  History of Stage I-IIIA endometrial adenocarcinoma of any grade

          -  1-5 years out from primary surgical treatment

          -  Adjuvant therapy may only have consisted of radiation or hormonal therapy

          -  No evidence of disease

        Exclusion Criteria:

          -  Previous treatment for other malignancies

          -  Did not undergo surgery for primary treatment of endometrial cancer

          -  Inability to read, write and speak fluent English

          -  Major cognitive impairment affecting ability to provide consent
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David M Kushner, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Wisconsin, Madison</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Wisconsin School of Medicine and Public Health</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://cancer.wisc.edu</url>
    <description>University of Wisconsin Carbone Cancer Center</description>
  </link>
  <results_reference>
    <citation>Onujiogu N, Johnson T, Seo S, Mijal K, Rash J, Seaborne L, Rose S, Kushner DM. Survivors of endometrial cancer: who is at risk for sexual dysfunction? Gynecol Oncol. 2011 Nov;123(2):356-9. doi: 10.1016/j.ygyno.2011.07.035.</citation>
    <PMID>21855974</PMID>
  </results_reference>
  <verification_date>September 2009</verification_date>
  <study_first_submitted>October 10, 2007</study_first_submitted>
  <study_first_submitted_qc>October 10, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 12, 2007</study_first_posted>
  <last_update_submitted>November 15, 2019</last_update_submitted>
  <last_update_submitted_qc>November 15, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 19, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Endometrial Cancer</keyword>
  <keyword>Sexual Function</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Endometrial Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

